SPOTLIGHT: FDA requiring suicide tracking in drug trials


For more than a decade, drug makers have not been required to pay much attention to the potential psychiatric side effects generated by experimental medicines. Now, however, new FDA rules will require drug makers to look closely at whether patients become suicidal during drug trials. Drug makers will now have to include a comprehensive suicide assessment scale into every trial. Article

Suggested Articles

The profit margins and management of Community Health Group raise questions about oversight of managed care insurers.

Financial experts are warning practices about the pitfalls of promoting medical credit cards to their patients.

A proposed rule issued by HHS on Tuesday would expand short-term coverage, a move Seema Verma said will have "virtually no impact" on ACA premiums.